234 related articles for article (PubMed ID: 35997319)
1. Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial.
Mosenzon O; Raz I; Wiviott SD; Schechter M; Goodrich EL; Yanuv I; Rozenberg A; Murphy SA; Zelniker TA; Langkilde AM; Gause-Nilsson IAM; Fredriksson M; Johansson PA; Wilding JPH; McGuire DK; Bhatt DL; Leiter LA; Cahn A; Dwyer JP; Heerspink HJL; Sabatine MS
Diabetes Care; 2022 Oct; 45(10):2350-2359. PubMed ID: 35997319
[TBL] [Abstract][Full Text] [Related]
2. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial.
Mosenzon O; Wiviott SD; Cahn A; Rozenberg A; Yanuv I; Goodrich EL; Murphy SA; Heerspink HJL; Zelniker TA; Dwyer JP; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Kato ET; Gause-Nilsson IAM; Fredriksson M; Johansson PA; Langkilde AM; Sabatine MS; Raz I
Lancet Diabetes Endocrinol; 2019 Aug; 7(8):606-617. PubMed ID: 31196815
[TBL] [Abstract][Full Text] [Related]
3. Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial.
Waijer SW; Vart P; Cherney DZI; Chertow GM; Jongs N; Langkilde AM; Mann JFE; Mosenzon O; McMurray JJV; Rossing P; Correa-Rotter R; Stefansson BV; Toto RD; Wheeler DC; Heerspink HJL
Diabetologia; 2022 Jul; 65(7):1085-1097. PubMed ID: 35445820
[TBL] [Abstract][Full Text] [Related]
4. Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
Zelniker TA; Raz I; Mosenzon O; Dwyer JP; Heerspink HHJL; Cahn A; Goodrich EL; Im K; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Gause-Nilsson I; Langkilde AM; Sabatine MS; Wiviott SD
JAMA Cardiol; 2021 Jul; 6(7):801-810. PubMed ID: 33851953
[TBL] [Abstract][Full Text] [Related]
5. Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.
Heerspink HJL; Jongs N; Chertow GM; Langkilde AM; McMurray JJV; Correa-Rotter R; Rossing P; Sjöström CD; Stefansson BV; Toto RD; Wheeler DC; Greene T;
Lancet Diabetes Endocrinol; 2021 Nov; 9(11):743-754. PubMed ID: 34619108
[TBL] [Abstract][Full Text] [Related]
6. The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58.
Mosenzon O; Wiviott SD; Heerspink HJL; Dwyer JP; Cahn A; Goodrich EL; Rozenberg A; Schechter M; Yanuv I; Murphy SA; Zelniker TA; Gause-Nilsson IAM; Langkilde AM; Fredriksson M; Johansson PA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS; Raz I
Diabetes Care; 2021 Aug; 44(8):1805-1815. PubMed ID: 34233928
[TBL] [Abstract][Full Text] [Related]
7. Decline in Estimated Glomerular Filtration Rate After Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Secondary Analysis of the DELIVER Randomized Clinical Trial.
Mc Causland FR; Claggett BL; Vaduganathan M; Desai A; Jhund P; Vardeny O; Fang JC; de Boer RA; Docherty KF; Hernandez AF; Inzucchi SE; Kosiborod MN; Lam CSP; Martinez F; Saraiva JFK; McGrath MM; Shah SJ; Verma S; Langkilde AM; Petersson M; McMurray JJV; Solomon SD
JAMA Cardiol; 2024 Feb; 9(2):144-152. PubMed ID: 37952176
[TBL] [Abstract][Full Text] [Related]
8. Dapagliflozin in Patients with Chronic Kidney Disease.
Heerspink HJL; Stefánsson BV; Correa-Rotter R; Chertow GM; Greene T; Hou FF; Mann JFE; McMurray JJV; Lindberg M; Rossing P; Sjöström CD; Toto RD; Langkilde AM; Wheeler DC;
N Engl J Med; 2020 Oct; 383(15):1436-1446. PubMed ID: 32970396
[TBL] [Abstract][Full Text] [Related]
9. Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories:
Levin A; Perkovic V; Wheeler DC; Hantel S; George JT; von Eynatten M; Koitka-Weber A; Wanner C;
Clin J Am Soc Nephrol; 2020 Oct; 15(10):1433-1444. PubMed ID: 32994159
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial.
Furtado RHM; Raz I; Goodrich EL; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Aylward P; Dalby AJ; Dellborg M; Dimulescu D; Nicolau JC; Oude Ophuis AJM; Cahn A; Mosenzon O; Gause-Nilsson I; Langkilde AM; Sabatine MS; Wiviott SD
Circulation; 2022 May; 145(21):1581-1591. PubMed ID: 35510542
[TBL] [Abstract][Full Text] [Related]
11. Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease.
Chertow GM; Vart P; Jongs N; Toto RD; Gorriz JL; Hou FF; McMurray JJV; Correa-Rotter R; Rossing P; Sjöström CD; Stefánsson BV; Langkilde AM; Wheeler DC; Heerspink HJL;
J Am Soc Nephrol; 2021 Sep; 32(9):2352-2361. PubMed ID: 34272327
[TBL] [Abstract][Full Text] [Related]
12. Dapagliflozin and Kidney Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the DELIVER Randomized Clinical Trial.
Mc Causland FR; Claggett BL; Vaduganathan M; Desai AS; Jhund P; de Boer RA; Docherty K; Fang J; Hernandez AF; Inzucchi SE; Kosiborod MN; Lam CSP; Martinez F; Saraiva JFK; McGrath MM; Shah SJ; Verma S; Langkilde AM; Petersson M; McMurray JJV; Solomon SD
JAMA Cardiol; 2023 Jan; 8(1):56-65. PubMed ID: 36326604
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial.
Wheeler DC; Jongs N; Stefansson BV; Chertow GM; Greene T; Hou FF; Langkilde AM; McMurray JJV; Rossing P; Nowicki M; Wittmann I; Correa-Rotter R; Sjöström CD; Toto RD; Heerspink HJL;
Nephrol Dial Transplant; 2022 Aug; 37(9):1647-1656. PubMed ID: 34850160
[TBL] [Abstract][Full Text] [Related]
14. Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program.
Neuen BL; Ohkuma T; Neal B; Matthews DR; de Zeeuw D; Mahaffey KW; Fulcher G; Blais J; Li Q; Jardine MJ; Perkovic V; Wheeler DC
Am J Kidney Dis; 2021 Jan; 77(1):23-34.e1. PubMed ID: 32971190
[TBL] [Abstract][Full Text] [Related]
15. Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial.
Heerspink HJL; Stefansson BV; Chertow GM; Correa-Rotter R; Greene T; Hou FF; Lindberg M; McMurray J; Rossing P; Toto R; Langkilde AM; Wheeler DC;
Nephrol Dial Transplant; 2020 Feb; 35(2):274-282. PubMed ID: 32030417
[TBL] [Abstract][Full Text] [Related]
16. Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction.
Furtado RHM; Bonaca MP; Raz I; Zelniker TA; Mosenzon O; Cahn A; Kuder J; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Ruff CT; Nicolau JC; Gause-Nilsson IAM; Fredriksson M; Langkilde AM; Sabatine MS; Wiviott SD
Circulation; 2019 May; 139(22):2516-2527. PubMed ID: 30882239
[TBL] [Abstract][Full Text] [Related]
17. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial.
Wheeler DC; Stefánsson BV; Jongs N; Chertow GM; Greene T; Hou FF; McMurray JJV; Correa-Rotter R; Rossing P; Toto RD; Sjöström CD; Langkilde AM; Heerspink HJL;
Lancet Diabetes Endocrinol; 2021 Jan; 9(1):22-31. PubMed ID: 33338413
[TBL] [Abstract][Full Text] [Related]
18. Reduction of Cardiovascular Risk and Improved Estimated Glomerular Filtration Rate by SGLT2 Inhibitors, Including Dapagliflozin, Is Consistent Across the Class: An Analysis of the Placebo Arm of EXSCEL.
Clegg LE; Heerspink HJL; Penland RC; Tang W; Boulton DW; Bachina S; Fox RD; Fenici P; Thuresson M; Mentz RJ; Hernandez AF; Holman RR
Diabetes Care; 2019 Feb; 42(2):318-326. PubMed ID: 30523029
[TBL] [Abstract][Full Text] [Related]
19. Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.
Jongs N; Greene T; Chertow GM; McMurray JJV; Langkilde AM; Correa-Rotter R; Rossing P; Sjöström CD; Stefansson BV; Toto RD; Wheeler DC; Heerspink HJL;
Lancet Diabetes Endocrinol; 2021 Nov; 9(11):755-766. PubMed ID: 34619106
[TBL] [Abstract][Full Text] [Related]
20. Class effects of SGLT2 inhibitors on cardiorenal outcomes.
Kluger AY; Tecson KM; Lee AY; Lerma EV; Rangaswami J; Lepor NE; Cobble ME; McCullough PA
Cardiovasc Diabetol; 2019 Aug; 18(1):99. PubMed ID: 31382965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]